MX382864B - Formulaciones de anticuerpos cristalinos. - Google Patents

Formulaciones de anticuerpos cristalinos.

Info

Publication number
MX382864B
MX382864B MX2017000526A MX2017000526A MX382864B MX 382864 B MX382864 B MX 382864B MX 2017000526 A MX2017000526 A MX 2017000526A MX 2017000526 A MX2017000526 A MX 2017000526A MX 382864 B MX382864 B MX 382864B
Authority
MX
Mexico
Prior art keywords
antibody formulations
crystalline antibody
crystalline
formulations
antibody crystals
Prior art date
Application number
MX2017000526A
Other languages
English (en)
Spanish (es)
Other versions
MX2017000526A (es
Inventor
Christi L Clogston
Timothy David Osslund
Twinkle R Christian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017000526A publication Critical patent/MX2017000526A/es
Publication of MX382864B publication Critical patent/MX382864B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2017000526A 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos. MX382864B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024399P 2014-07-14 2014-07-14
PCT/US2015/040211 WO2016010924A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations

Publications (2)

Publication Number Publication Date
MX2017000526A MX2017000526A (es) 2017-08-02
MX382864B true MX382864B (es) 2025-03-13

Family

ID=53716611

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000526A MX382864B (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.
MX2021006003A MX2021006003A (es) 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006003A MX2021006003A (es) 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos.

Country Status (7)

Country Link
US (2) US10611850B2 (enExample)
EP (2) EP3169709B1 (enExample)
JP (4) JP6783223B2 (enExample)
AU (3) AU2015289967A1 (enExample)
CA (1) CA2954773C (enExample)
MX (2) MX382864B (enExample)
WO (1) WO2016010924A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2810003T3 (es) 2011-11-18 2021-03-08 Regeneron Pharma Micropartícula que contiene proteína terapéutica recubierta con polímero biodegradable para uso médico
US10611850B2 (en) * 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
EP3362041A1 (en) * 2015-10-16 2018-08-22 Regeneron Pharmaceuticals, Inc. Stable protein compositions
WO2019099427A1 (en) * 2017-11-14 2019-05-23 The University Of North Carolina At Chapel Hill Compositions and methods for stabilization of proteins
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10611850B2 (en) * 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
CA2954767A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations

Also Published As

Publication number Publication date
US11773184B2 (en) 2023-10-03
US20170198058A1 (en) 2017-07-13
US10611850B2 (en) 2020-04-07
MX2021006003A (es) 2021-07-06
JP2017525679A (ja) 2017-09-07
AU2015289967A1 (en) 2017-02-02
JP2020169200A (ja) 2020-10-15
JP2023055977A (ja) 2023-04-18
AU2021201409A1 (en) 2021-03-25
MX2017000526A (es) 2017-08-02
JP2018141004A (ja) 2018-09-13
AU2024205016A1 (en) 2024-08-15
EP3929218A1 (en) 2021-12-29
CA2954773C (en) 2023-10-03
WO2016010924A1 (en) 2016-01-21
JP6783223B2 (ja) 2020-11-11
EP3169709B1 (en) 2021-05-12
JP7264853B2 (ja) 2023-04-25
CA2954773A1 (en) 2016-01-21
US20200299410A1 (en) 2020-09-24
EP3169709A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
CL2016001871A1 (es) Anticuerpos humanos para pd-1
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691991A1 (ru) Мультиспецифические антитела
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MY176285A (en) Anti-fcrh5 antibodies
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX377774B (es) Formulaciones de proteinas.
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
EA201691203A1 (ru) Твёрдые формы тенофовира
MX2015010789A (es) Anticuerpos anti-pcsm.
UA114708U (uk) Тяговий привід електробуса
TWD175566S (zh) 雪鏡
TWD173435S (zh) 土除
UY37009A (es) Formulaciones granuladas de giberelina
TH1501005368A (th) สารเตรียมเชิงซ้อนที่รวมถึง วัลซาร์แทน และ โรซูวาสแตติน แคลเซียม และ วิธีการผลิต สำหรับสิ่งนั้น